title: Enhancement after feline immunodeficiency virus vaccination.
abstract: Cats were vaccinated with one of the three preparations: purified feline immunodeficiency virus (FIV) incorporated into immune stimulating complexes (ISCOMs), recombinant FIV p24 ISCOMs, or a fixed, inactivated cell vaccine in quil A. Cats inoculated with the FIV ISCOMs or the recombinant p24 ISCOMs developed high titres of antibodies against the core protein p24 but had no detectable antibodies against the env protein gp120 or virus neutralising antibodies. In contrast, all of the cats inoculated with the fixed, inactivated cell vaccine developed anti-env antibodies and four of five had detectable levels of neutralising antibody. However, none of the vaccinated cats were protected from infection after intraperitoneal challenge with 20 infectious units of FIV. Indeed there appeared to be enhancement of infection after vaccination as the vaccinated cats become viraemic sooner than the unvaccinated controls, and 100% of the vaccinated cats became viraemic compared with 78% of the controls. The mechanism responsible for this enhancement remains unknown.
authors.affiliation: University of Glasgow, Department of Veterinary Pathology, UK.
authors.forename: M J
authors.initials: MJ
authors.lastname: Hosie
authors.forename: R
authors.initials: R
authors.lastname: Osborne
authors.forename: G
authors.initials: G
authors.lastname: Reid
authors.forename: J C
authors.initials: JC
authors.lastname: Neil
authors.forename: O
authors.initials: O
authors.lastname: Jarrett
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D002415:Cats; D016181:Feline Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D015683:Gene Products, gag / Q000008:administration & dosage / Q000276:immunology*; D016089:Immunodeficiency Virus, Feline / Q000254:growth & development / Q000276:immunology*; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology; D015682:Retroviridae Proteins, Oncogenic / Q000008:administration & dosage / Q000276:immunology*; D014611:Vaccination / Q000662:veterinary*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014766:Viremia / Q000662:veterinary
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D015683:Gene Products, gag; D011994:Recombinant Proteins; D015682:Retroviridae Proteins, Oncogenic; D015164:Vaccines, Inactivated; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine; C074662:p24 protein, Feline immunodeficiency virus